Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.905 USD | -1.90% | +1.89% | +58.76% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 84.86M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -27M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-2.76
x | Employees | 15 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.9% |
Latest transcript on Aileron Therapeutics, Inc.
1 day | -1.70% | ||
1 week | +4.32% | ||
Current month | -25.26% | ||
1 month | -15.44% | ||
3 months | -16.58% | ||
6 months | +306.15% | ||
Current year | +62.53% |
Managers | Title | Age | Since |
---|---|---|---|
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Director of Finance/CFO | 48 | 23-09-30 | |
David Annis
CTO | Chief Tech/Sci/R&D Officer | 51 | 07-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-06-18 | |
Alan Musso
BRD | Director/Board Member | 61 | 23-10-30 |
Brian Windsor
CEO | Chief Executive Officer | 57 | 23-10-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 4.93 | -1.40% | 27 031 |
24-04-26 | 5 | 0.00% | 85,369 |
24-04-25 | 5 | +1.42% | 80,550 |
24-04-24 | 4.93 | +3.79% | 102,254 |
24-04-23 | 4.75 | 0.00% | 67,716 |
Delayed Quote Nasdaq, April 29, 2024 at 11:11 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.53% | 84.86M | |
-2.44% | 103B | |
+1.93% | 95.28B | |
+1.69% | 22.15B | |
-15.42% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.12% | 16.05B | |
+4.14% | 13.68B | |
+35.44% | 12.17B |
- Stock Market
- Equities
- ALRN Stock